Corporate News
16 January 2024
We are very proud to present our last paper in collaboration with the Institute of Neuroscience of the Universitat de Barcelona, the CiQUS – Center for Research in […]
18 October 2023
Sigma (σ) receptor subtypes, σ1 and σ2, are targets of wide pharmaceutical interest. σ1 receptor ligands are under evaluation in clinical trials for the treatment of diseases such as […]
11 September 2023
A major bottleneck in drug discovery, particularly when targeting transmembrane proteins such as G-coupled receptor proteins (GPCRs), is the challenge of replicating in vitro the precise microenvironment conditions […]
7 July 2023
Our portfolio of #GPCR#fluorescent ligands is growing.We have just added to our catalogue more fluorescent ligands for the AT1 receptor, CELT-145 and CELT-252. The Angiotensin AT1 receptor belongs to the […]
27 March 2023
Celtarys Research collaborates with several research groups in Europe for the validation of our products in different assays commonly used in drug discovery, always with the […]
3 March 2023
Our portfolio of #GPCR#fluorescent ligands is growingWe have just added to our catalogue more fluorescent ligands for the C5a receptor, CELT-58 and CELT-68. The C5a anaphylatoxin chemotactic receptor 1 (C5aR, also […]
19 December 2022
We are glad to announce that Celtarys Research has reached a strategic research cooperation agreement with the European platform EU-OPENSCREEN (https://www.eu-openscreen.eu ), a not-for-profit European Research Infrastructure […]
9 November 2022
The XIV meeting of the Spanish Drug Discovery Network (SDDN) will take place in Granada, Spain, on November 24 and 25, 2022. This international conference has […]
20 September 2022
To date, it has been reported that about 800 GPCRs are encoded by the human genome. Some of them have known ligands available which led to the […]